Challenging issues in molecular-targeted therapy

References

• EstellerMCancer epigenomicsNat Rev Genet2007828629817339880
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe epigenomics of cancerCell200712868369217320506
   PubMed Web of Science ®Google Scholar
• YooCBJonesPAEpigenetic therapy of cancerNat Rev Drug Disc200653750
   PubMed Web of Science ®Google Scholar
• QianDZWangXKachhapSKThe histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584Cancer Res2004646626663415374977
   PubMed Web of Science ®Google Scholar
• VenkateswarluSDawsonDMSt ClairPAutocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cellsOncogene200221788611791178
   PubMed Web of Science ®Google Scholar
• JacksonJGSt ClairPSliwkowskiMXBlockade of epidermal growth factor- or heregulin- dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effectsCancer Res2004642601260915059917
   PubMed Web of Science ®Google Scholar
• GaspariniGLongoRFanelliMCombination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questionsJ Clin Oncol20051295131115718328
   PubMed Web of Science ®Google Scholar
• EzzianeZMolecular docking and analysis of survivin delta-ex3 isoform proteinThe Open Medicinal Chemistry Journal200821620
   PubMedGoogle Scholar
• von MehrenMSchilderRJChengJDA phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignanciesAnn Oncol200819101802180918497430
   PubMed Web of Science ®Google Scholar
• SabnaniIZuckerMJRosensteinEDA novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamideRheumatology2009481495218815156
   PubMed Web of Science ®Google Scholar
• O’ByrneKJDansonSDunlopDCombination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non-small-cell lung cancerJ Clin Oncol200725223266327317664473
   PubMed Web of Science ®Google Scholar
• KonstasAGPMikropoulosDDimopoulosATSecond-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapyBr J Ophthalmol2008921498150218703549
   PubMed Web of Science ®Google Scholar
• SherwoodMBCravenERChonCTwice-daily 0.2% brimo-nidine−0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial for the Combigan Study Groups I and IIArch Ophthalmol20061241230123816966616
   PubMed Web of Science ®Google Scholar
• BraitehFSorianoAOGarcia-ManeroGPhase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersClin Can Res20081462966301
   PubMed Web of Science ®Google Scholar
• CandelariaMGallardo-RincónDArceCA phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumorsAnn Oncol20071891529153817761710
   PubMed Web of Science ®Google Scholar
• SchrumpDSFischetteMRNguyenDMClinical and molecular responses in lung cancer patients receiving romidepsinClin Can Res200814188198
   PubMed Web of Science ®Google Scholar
• BerensonJRYangHHSadlerKPhase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJ Clin Oncol200624693794416418495
   PubMed Web of Science ®Google Scholar
• BerensonJRMatousJSwiftRAPhase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myelomaClin Can Res20071317621768
   PubMed Web of Science ®Google Scholar
• GoldsteinBJFeinglosMNLuncefordJKEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care2007301979198717485570
   PubMed Web of Science ®Google Scholar
• RosenstockJSugimotoDStrangePInsulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patientsDiabetes Care20062955455916505505
   PubMed Web of Science ®Google Scholar
• DyGKBruzekLMCroghanGAA phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancerClin Can Res20051118771883
   PubMed Web of Science ®Google Scholar
• DiérasVBonneterreJLaurenceVPhase I combining a p-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignanciesClin Can Res20051162566260
   PubMed Web of Science ®Google Scholar
• ForsterMKayeSOzaAA Phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancerClin Can Res20071341784184
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMVenkatesanNMActivity of the dual kinase inhibitor lapatinib (GW572016) against HER-2 overexpressing and trastuzumab-treated breast cancer cellsCancer Res20066631630163916452222
   PubMed Web of Science ®Google Scholar
• PegramMYeonCKuNPhase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER-2 protooncogene and vascular endothelial growth factor (VEGF) Proc. SABCS 2004 [abstract 3039]Breast Cancer Res Treat2005902193214
   Google Scholar
• MilanoANastiGLaffaioliRVFirst line targeted therapies in breast cancer: focus on bevacizumabBiologics: Targets and Therapy200711310
   PubMedGoogle Scholar
• MillerKDChapLIHolmesFARandomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerJ Clin Oncol2005a23792a799a15681523
   PubMed Web of Science ®Google Scholar
• ZhouYSongLHu YiPBlockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosisCancer Res200666140441116397255
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckKThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Ther200112859412467226
   PubMed Web of Science ®Google Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacolo Rev200658621681
   PubMed Web of Science ®Google Scholar
• Tufts Center for the Study of Drug DevelopmentRecent news from the Tufts Center for the Study of Drug Development2001 [Cited Jan 10, 2009]. Available from: http://csdd.tufts.edu/NewsEvents.
   Google Scholar
• ScheinPSSchefflerBBarriers to efficient development of cancer therapeuticsClin Can Res2006121132433248
   PubMed Web of Science ®Google Scholar
• NewellPVillanuevaAFriedmanSLExperimental models of hepatocellular carcinomaJ Hepatol20084885887918314222
   PubMed Web of Science ®Google Scholar
• HuynhHSooKCChowPKXenografts of human hepatocellular carcinoma: a useful model for testing drugsClin Can Res20061243064314
   PubMed Web of Science ®Google Scholar
• KerbelRSHuman tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improvedCancer Biol Ther20032S134S13914508091
   PubMed Web of Science ®Google Scholar